 The FDA has approved Heron Therapeutics Incs NASDAQ: HRTX supplemental application for Zynrelef bupivacaine and meloxicam extended-release solution to expand the indication. Zynrelef is now indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures. 